Quick Answer
Solid Biosciences Inc. reported Net Income Loss of -$117.22 million for the year ending 2019.
- Solid Biosciences Inc. showed a decrease of -56.7% in Net Income Loss from 2018 to 2019.
- This data is from Solid Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2020.
- XBRL data for this metric is available from 2016 to 2019 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$12.82 million | Q2 2017: -$11.31 million | Q3 2017: -$13.51 million | Q4 2017: -$14.49 million | Q1 2018: -$15.88 million | Q2 2018: -$17.98 million | Q3 2018: -$19.02 million | Q4 2018: -$21.92 million | Q1 2019: -$29.58 million | Q2 2019: -$26.53 million | Q3 2019: -$29.26 million | Q1 2020: -$26.69 million | Q2 2020: -$18.99 million | Q3 2020: -$21.25 million | Q1 2021: -$16.90 million | Q2 2021: -$18.70 million | Q3 2021: -$17.98 million.
- Over the full 4 years of available data (2016 to 2019), Solid Biosciences Inc.'s Net Income Loss has declined by 444.2%.
- Historical annual values: Fiscal year 2019: -$117.22 million | Fiscal year 2018: -$74.80 million | Fiscal year 2017: -$52.12 million | Fiscal year 2016: -$21.54 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: